Curated News
By: NewsRamp Editorial Staff
August 14, 2026
Helus Pharma Completes Enrollment in Phase 3 MDD Study, Reports Q2 Results
TLDR
- Helus Pharma completed enrollment in its Phase 3 APPROACH trial, positioning for topline data in Q4 2026, a potential edge in the depression market.
- The Phase 3 PARADIGM program includes APPROACH and EMBRACE studies, with EXTEND follow-up, evaluating HLP003 for major depressive disorder.
- Helus Pharma's novel serotonergic agonists aim to provide durable mental health improvements, addressing unmet needs in depression and anxiety.
- Helus Pharma, formerly Cybin, is developing HLP004 for anxiety after Phase 2 showed significant improvement, with next study design by Q3.
Impact - Why it Matters
This news matters because Helus Pharma's advancements in Phase 3 trials for HLP003 could lead to a new treatment option for major depressive disorder, a condition affecting millions worldwide. The completion of enrollment brings the company closer to potential FDA approval, which could significantly impact the mental health treatment landscape. Investors and patients alike are keenly watching these developments, as positive topline data could position Helus Pharma as a leader in the emerging field of serotonergic agonists, offering hope for those who have not responded to existing therapies.
Summary
Helus Pharma, the commercial operating name of Cybin Inc., has announced significant progress in its clinical programs, including the completion of enrollment in its Phase 3 pivotal study APPROACH for HLP003 in major depressive disorder (MDD), with topline data expected in the fourth quarter of 2026. The company also continues to advance its EMBRACE study and the EXTEND rollover study, while HLP004 for generalized anxiety disorder (GAD) is progressing following positive Phase 2 results. Financially, Helus Pharma reported cash of $166.4 million as of June 30, 2026, and a quarterly net loss of $47.8 million, reflecting increased investment in its Phase 3 trials.
Helus Pharma is developing novel serotonergic agonists (NSAs) designed to promote neuroplasticity and address mental health conditions. HLP003 has received Breakthrough Therapy Designation from the U.S. FDA, underscoring its potential in MDD. The company is also advancing HLP005 toward candidate selection, with a viable candidate expected in 2027. These developments highlight Helus Pharma's commitment to addressing the large unmet need in depression and anxiety treatment.
For more details, visit the full press release at https://ibn.fm/yfpOW. This news was disseminated by TinyGems, a communications platform for innovative companies, and includes links to TinyGems and the Dynamic Brand Portfolio.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Completes Enrollment in Phase 3 MDD Study, Reports Q2 Results
